Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7)
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1–7)
Authors
Keywords
Immunostaining, Ascites, Carcinomas, Cancer treatment, Immune receptors, Tyrosine kinases, Analysis of variance, Tumor angiogenesis
Journal
PLoS One
Volume 9, Issue 1, Pages e85891
Publisher
Public Library of Science (PLoS)
Online
2014-01-23
DOI
10.1371/journal.pone.0085891
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression and Correlation of Hypoxia-inducible Factor-1α, Vascular Endothelial Growth Factor and Microvessel Density in Experimental Rat Hepatocarcinogenesis
- (2013) W Wang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Role of angiogenesis in the pathogenesis of cancer
- (2012) Paulo M. Hoff et al. CANCER TREATMENT REVIEWS
- Angiotensin-(1–7): beyond the cardio-renal actions
- (2012) Danielle G. Passos-Silva et al. CLINICAL SCIENCE
- Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: Role of iNOS and VEGF
- (2012) Sawsan A. Zaitone et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Alfa-Lipoic Acid Controls Tumor Growth and Modulates Hepatic Redox State in Ehrlich-Ascites-Carcinoma-Bearing Mice
- (2012) M. AL Abdan TheScientificWorldJOURNAL
- An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect
- (2011) Rodrigo Araujo Fraga-Silva et al. Clinics
- Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials
- (2011) Fabio A.B. Schutz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- In-Vivo Visualization of Tumor Microvessel Density and Response to Anti-Angiogenic Treatment by High Resolution MRI in Mice
- (2011) Roland T. Ullrich et al. PLoS One
- Angiotensin II Receptor Blockers and Risk of Cancer: Cause for Concern?
- (2010) Frederic Rahbari-Oskoui AMERICAN JOURNAL OF KIDNEY DISEASES
- The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells
- (2010) Catrin Schult et al. BMC CANCER
- Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy
- (2010) Minna Taskinen et al. EUROPEAN JOURNAL OF CANCER
- Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice
- (2010) Mona El-Azab et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies
- (2010) LANCET ONCOLOGY
- Sorafenib exerts anti-glioma activity in vitro and in vivo
- (2010) Markus D. Siegelin et al. NEUROSCIENCE LETTERS
- Blocking Angiotensin II Type 1 Receptor Triggers Apoptotic Cell Death in Human Pancreatic Cancer Cells
- (2010) Qiaoke Gong et al. PANCREAS
- Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor
- (2009) H. Huynh et al. MOLECULAR CANCER THERAPEUTICS
- Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor
- (2009) D. R. Soto-Pantoja et al. MOLECULAR CANCER THERAPEUTICS
- The renin-angiotensin system and malignancy
- (2008) E. I. Ager et al. CARCINOGENESIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation